Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:ENTX

Entera Bio Q1 2026 Earnings Report

Entera Bio logo
$1.61 -0.02 (-1.04%)
As of 09:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Entera Bio EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Entera Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Entera Bio Announcement Details

Quarter
Q1 2026
Date
5/8/2026
Time
After Market Closes
Conference Call Date
Friday, May 8, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Entera Bio's Q2 2026 earnings is estimated for Friday, August 14, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Entera Bio's Q1 2026 Press ReleasePress Release
(8-K)
Entera Bio's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Entera Bio Earnings Headlines

Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
June 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/23/3315992/0/en/Positive-FDA-Feedback-on-Phase-3-Brings-Entera-Bio-s-Oral-Osteoporosis-Pill-One-Step-Closer-to-Market.html
ENTX stock on track for best day in over 5 years — what’s driving the rally?
June 22, 2026  |  msn.comhttps://www.msn.com/en-in/money/general/entx-stock-on-track-for-best-day-in-over-5-years-what-s-driving-the-rally/ar-AA26hPFK
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
June 29 at 1:00 AM  |  Porter & Company (Ad)
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with ...
June 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/entera-bio-receives-positive-fda-feedback-on-12-month-registrational-phase-3-study-for-eb613---the-first-oral-anabolic-tablet-in-development-for-postmenopausal-women-with-osteoporosis-1036264979
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315282/0/en/entera-bio-receives-positive-fda-feedback-on-12-month-registrational-phase-3-study-for-eb613-the-first-oral-anabolic-tablet-in-development-for-postmenopausal-women-with-osteoporosi.html
After Novo Nordisk’s Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story?
June 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ENTX/pressreleases/2557203/after-novo-nordisks-oral-peptide-playbook-made-history-could-entera-be-the-next-big-peptide-story/
See More Entera Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Entera Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entera Bio and other key companies, straight to your email.

About Entera Bio

Entera Bio (NASDAQ:ENTX), Inc. is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis. EB613 entered Phase 1 clinical trials to assess safety, tolerability and pharmacokinetics in healthy volunteers. In parallel, Entera Bio is advancing EB612, an oral tumor necrosis factor (TNF) antagonist, toward early‐stage clinical development for inflammatory diseases such as rheumatoid arthritis and Crohn’s disease.

Since its founding in 2010, Entera Bio has established operations in Newton, Massachusetts, and research facilities in Israel, positioning the company at the intersection of North American and international biopharmaceutical innovation. Its leadership team combines expertise in peptide chemistry, clinical development, regulatory affairs and commercial strategy. Entera Bio plans to collaborate with established pharmaceutical partners to support late‐stage clinical programs and the global commercialization of its oral peptide product candidates.

View Entera Bio Profile
Earnings Tools